top of page

(The names on this page have been changed to protect the identity of our clients. These are real test results for real people.)

Emma Bryo
MGI Blueprint

Emma Bryo’s case study highlighted

high-impact genetic findings in estrogen metabolism, thyroid signaling, folate metabolism, blood sugar balance, and histamine response, helping reveal how multiple pathways may have been shaping her health experience at the same time.

MGI Blueprint.png

How Emma Went From “IVF Recommended” to Natural Conception
A multi-pathway genomic approach to fertility optimization

Name:

Emma Bryo

Age:

31

Phase:

Trying to Conceive (TTC)

History:

Advised IVF after unsuccessful attempts to conceive

Primary Concerns:

Irregular cycles, hormonal imbalance, fatigue, inflammatory symptoms​

Time to Outcome:

Several months of targeted support

Outcome:

Natural conception, currently expecting

​

🧬 MGI Insight

Using the MGI Blueprint,

Emma’s results revealed multiple high-impact pathways interacting simultaneously:

1. Estrogen Metabolism

Genetic variants suggested reduced efficiency in estrogen clearance, contributing to hormonal imbalance and potential cycle disruption.

2. Thyroid Signaling

Variants associated with thyroid hormone regulation indicated potential downstream effects on ovulation, metabolism, and energy production.

3. Folate Metabolism

Reduced methylation efficiency pointed toward increased nutritional demands for folate-dependent processes critical in preconception health.

4. Blood Sugar Regulation

Genetic tendencies toward glucose instability may have contributed to hormonal fluctuations and systemic stress.

5. Histamine Response

Elevated histamine sensitivity suggested an inflammatory component influencing overall physiological balance.

​

Intervention Direction

Rather than a one-size-fits-all protocol, Emma’s care was guided by pathway-specific support, including:

  • Targeted nutritional strategies to support methylation and folate pathways

  • Lifestyle and dietary adjustments to stabilize blood sugar

  • Support for estrogen metabolism and detoxification pathways

  • Nervous system and inflammatory support aligned with histamine sensitivity

  • Thyroid-supportive interventions based on her genomic profile

This approach allowed for precision without overwhelm, focusing on the most impactful areas first.

 

Outcomes

Over the course of a few months, Emma experienced:

  • Improved cycle regularity

  • Increased energy and stability

  • Reduction in inflammatory symptoms

  • Greater overall physiological resilience

Most significantly:

She conceived naturally and is now expecting

​

The MGI Blueprint provided:

  • A structured way to identify key biological drivers

  • Clarity on where to focus first

  • A framework for personalized, pathway-based support

  • For practitioners, this translates to:

  • More precise decision-making

  • Greater confidence in care planning

  • The ability to uncover contributors that standard approaches may miss

​

Copy of MGI PGX Report.png

Emma Bryo
MGI PGx

The MGI Pharmacogenomics (PGX) Report helps mothers understand how their unique genetics may influence their response to medications commonly used during pregnancy, birth, and postpartum recovery.

 

By identifying genetic variations that affect drug metabolism and sensitivity, the report can support more informed conversations with care providers and more personalized decisions around pain management, anesthesia, and medication use.

Preparing for Birth:
Using Pharmacogenomics to Personalize the Hospital Experience
 

Following successful conception, Emma is planning her hospital birth.

Like many mothers, she is presented with standardized options for:

  • Pain management

  • Medications during labor

  • Postpartum recovery protocols

However, these recommendations are typically not individualized,

particularly when it comes to how the body processes medications.

​

🧬 MGI + PGx Insight

Using her pharmacogenomic (PGx) profile,

Emma and her care team were able to explore how her body may respond

to commonly used medications in a hospital setting.

​

Key areas of focus included:

​

1. Pain Management Response

Genetic variants influencing drug metabolism (e.g., liver enzyme activity)

provided insight into how she may process certain analgesics.

This allowed for more informed discussions around:

  • Standard pain medications

  • Alternative options

  • Dosing considerations

​

2. Anesthesia Considerations

Variants related to drug metabolism and nervous system sensitivity

offered additional context for how her body may respond to:

Epidural medications

Other anesthetic agents

​

3. Postpartum Medication Planning

Her PGx profile also provided insight into how she may respond to:

Pain relief medications

Antibiotics (if needed)

Mood-related medications in the postpartum window

​

In standard care, medication response is often:

  • Trial-and-error

  • Reactive rather than proactive

  • Based on population averages

​

By integrating PGx insights,

Emma is able to approach her birth plan with:

  • Greater clarity

  • More informed consent

  • A deeper understanding of how her body may respond

​

Emma’s journey now reflects continuity across the maternal timeline:

Preconception: Identified and supported key pathways

Conception: Achieved pregnancy naturally

Pregnancy: Preparing for birth with individualized insight

This creates a more cohesive and informed experience rather than fragmented stages of care.

​

MGI is not limited to a single outcome.

We provide a framework for decision-making across the entire maternal timeline:

Fertility

Pregnancy

Birth

Postpartum

And Beyond

bottom of page